GlassScriptPhysician profile
Taimur Khan
NPI 1235387358
$4,214.46
in general payments reported to CMS, 2019-2025
31 companies · $1,581 in 2025
The $1,581 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $184 · 2021: $303 · 2022: $456 · 2023: $589 · 2024: $715 · 2025: $1,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,549 · Grant: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.27 |
| Grant | $335.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $798.95 | 2019-2025 | |
| Gilead Sciences, INC. | $423.11 | 2020-2025 | |
| Celgene Corporation | $379.75 | 2021-2024 | Zeposia |
| Cook Medical LLC | $347.96 | 2019-2022 | |
| Ardelyx, INC. | $302.89 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $289.24 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.26 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $222.38 | 2019-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $203.77 | 2022-2025 | Dupixent |
| Genzyme Corporation | $175.84 | 2022-2025 | |
| Pfizer INC. | $152.67 | 2019-2025 | |
| Lilly USA, LLC | $87.48 | 2023-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $75.48 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $66.48 | 2024-2025 | Voquezna |
| Olympus America INC. | $47.36 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.91 | 2019-2024 | Dificid |
| Boston Scientific Corporation | $39.03 | 2020-2023 | Hydratome Rx 44 |
| Madrigal Pharmaceuticals | $38.09 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $26.77 | 2022 | |
| Sandoz INC. | $24.87 | 2025 | Hyrimoz |
| Ucb, INC. | $24.48 | 2019 | |
| Conmed Corporation | $24.47 | 2025 | Conmed Dilation |
| Biocon Biologics INC | $20.48 | 2023 | Hulio |
| Ipsen Biopharmaceuticals, INC | $20.32 | 2025 | Iqirvo |
| Allergan, INC. | $18.26 | 2019 | |
| Intercept Pharmaceuticals, INC. | $15.68 | 2021 | |
| Daiichi Sankyo INC. | $15.41 | 2019 | |
| Braintree Laboratories, INC. | $15.32 | 2024 | Suflave |
| Organon LLC | $14.25 | 2023 | Renflexis, Hadlima |
| Csl Behring | $11.50 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taimur Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.